Lonza Group

Lonza Group AG
Aktiengesellschaft
Traded as SIX: LONN, SGX: O6Z
Industry Chemicals
biotechnology
Founded 1897
Headquarters Basel, Switzerland
Key people
 Richard Ridinger (CEO), Rolf Soiron (Chairman)
Products Biopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products
Revenue CHF 2.680 billion (2010)[1]
CHF 374 million (2010)[1]
Profit CHF 291 million (2010)[1]
Total assets CHF 4.778 billion (end 2010)[1]
Total equity CHF 2.387 billion (end 2010)[1]
Number of employees
 11,400 (2012)
Website www.lonza.com

Lonza Group is a Swiss multinational, chemicals and biotechnology company, head-quartered in Basel, with R&D centres in Belgium, France, Germany, Spain, U.K., Singapore, United States and Genome Valley, India.[2][3] The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.[4][5]

History

Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange. The company has expanded in the United States and acquired smaller biopharmaceutical units in recent years. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides.[6] On the 15th of August 2016, the group announced its intention to acquire InterHealth Nutraceuticals,[7] a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements. The acquisition of the US based company will be done at a value of up to USD 300m.

References

This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.